Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer

International Journal of Cancer

Volumn 112, Issue 2, 2004, Pages 335-340

  Sahoo, Sanjeeb K ^a   Ma, Wenxue ^a   Labhasetwar, Vinod ^a,b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antiproliferative effect; Biodegradable polymer; Drug delivery; Ligand, tumor inhibition; Sustained release

Indexed keywords

CREMOPHOR; NANOPARTICLE; PACLITAXEL; TRANSFERRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL LINE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; SUSTAINED DRUG RELEASE; TUMOR REGRESSION;

ANIMALS; BIOCOMPATIBLE MATERIALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; MALE; MICE; MICE, NUDE; NANOTECHNOLOGY; PACLITAXEL; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TRANSFERRIN; VEHICLES;

EID: 4544358907     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20405     Document Type: Article

References (41)

1. Melmed GY, Kwan L, Reid K, Litwin MS. Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology 2002;59:103-9.
2. Bosland MC, Dreef-Van Der Meulen HC, Sukumar S, Ofner P, Leav I, Han X, Liehr JG. Multistage prostate carcinogenesis: the role of hormones. Princess Takamatsu Symp 1991;22:109-23.
3. Caplan A, Kratz A. Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol 2002;117 Suppl:S104-8.
4. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer 2003;98:1417-22.
5. Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL, Sullivan LD. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996;47:708-12.
6. Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002;8:1237-41.
7. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr., Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
8. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561-87.
9. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42:439-62.
10. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharmacol Des 1999;5:443-51.
11. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983;36:539-45.
12. Wang F, Jiang X, Yang DC, Elliott RL, Head JF. Doxorubicin-gallium- transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res 2000;20:799-808.
13. Joshee N, Bastola DR, Cheng PW. Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum Gene Ther 2002;13:1991-2004.
14. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54:631-51.
15. Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 2003;20:212-20.
16. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J Pharm Sci 1998;87:1229-34.
17. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res 2002;19:1137-43.
18. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 2002;233:51-9.
19. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992;30:444-50.
20. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solid-state solubility of drug in PLGA/PLA polymers influences encapsulation and release of hydrophobic drugs from nanoparticles. J Pharm Sci 2004;93:1804-14.
21. Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model. J Control Release 1998; 54:201-11.
22. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002;82:105-14.
23. Au JL, Li D, Gan Y, Gao X, Johnson AL, Johnston J, Millenbaugh NJ, Jang SH, Kuh HJ, Chen CT, Wientjes MG. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 1998;58:2141-8.
24. Markman M. Managing taxane toxicities. Support Care Cancer 2003; 11:144-7.
25. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999;12:565-71.
26. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A 2003;100:6039-44.
27. Guillemard V, Saragovi HU. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res 2001;61:694-9.
28. Vega J, Ke S, Fan Z, Wallace S, Charsangavej C, Li C. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer. Pharm Res 2003;20:826-32.
29. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin- polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002;99:130-7.
30. Widera A, Norouziyan F, Shen WC. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 2003;55:1439-66.
31. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61:3027-32.
32. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
33. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85.
34. Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res 2000;60:4146-51.
35. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 2003;86:33-48.
36. Winternitz CI, Jackson JK, Oktaba AM, Burt HM. Development of a polymeric surgical paste formulation for taxol. Pharm Res 1996;13:368-75.
37. Wagner E, Curiel D, Cotten M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv Drug Deliv Rev 1994;14:113-35.
38. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55:329-47.
39. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002;16:1217-26.
40. Panyam J, Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 2004;1:77-84.
41. Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 2002;22:225-50.